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Abstract 
Objective: To evaluate adherence to care standards for people with diabetes (PWDs) 
on insulin therapy versus PWDs who are not on insulin therapy, controlling for 
social determinants. 
Research design and methods: Utilizing the United States 2015 Behavioral Risk Fac-
tor Surveillance System Survey, this study used logistic regression analyses to 
estimate differences in self-care behaviors, healthcare provider quality of care, 
and diabetic complications for individuals on insulin therapy and individuals not 
on insulin therapy. 
Results: PWDs on insulin therapy are more likely to adhere to self-care measures 
(self-glucose checks [OR: 7.57], self-foot checks [OR: 1.27], diabetes class partic-
ipation [OR: 1.96]), adherence to provider care standards (diabetes-related doc-
tor visits [OR: 1.24], comprehensive foot exam [OR: 1.80], dilated eye exam [OR: 
1.34]), and to self-report diabetic complications (retinopathy [OR: 2.77], kidney 
disease [OR:2.14]), controlling for sociodemographic variables. 
Conclusion: PWDs on insulin and their healthcare providers are more likely to meet 
the treatment goals set by the American Diabetes Association. PWDs on insulin 
therapy may have better overall relationships with providers due to a reduction 
in stigmatization based on the social construction of diabetes. 
Keywords: US, Diabetes, Standard of care, Social construction, Treatment outcomes, 
Insulin therapy 
digitalcommons.unl.edu
A N D E R S E N  &  G I B B S  I N  P R I M A RY  C A R E  D I A B E T E S  1 2  ( 2 0 1 8 )     2
1. Introduction 
More than 29 million Americans are living with diabetes, and an additional 
89 million are living with prediabetes [1]. Diabetes is the seventh leading 
cause of death in the United States, and can lead to complications such as 
kidney failure, diabetic retinopathy, heart disease, and lower-limb amputa-
tions [1]. Diabetes care accounts for 20% of the national healthcare spend-
ing, a concern as costs to patients and taxpayers increase [1]. Research from 
the Centers for Disease Control and Prevention (CDC) [1] indicates that if 
current trends persist, one-third of Americans will develop diabetes in their 
lifetime and lose, on average, 10–15 years of life. Given these statistics it 
is important to understand how the social construction of diabetes, treat-
ment types and social determinants affect how patients and their providers 
care for diabetes. From an agency perspective, people/person with diabetes 
(PWDs) have various daily self-management decisions to make and activities 
to undertake [2], which may be associated with low adherence to regimen 
[3]. Generally speaking, self-management of diabetes is a complex and im-
portant strategy to improve quality of life, which means taking into account 
the interactive effects diabetes has on not only health, but also relationships 
and other sociopsychological factors [4]. While self-management of diabetes 
is important for healthy lifestyle, the role and relationship between health 
care professionals are intricately linked in order to achieve quality well-be-
ing for PWDs. The American Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD) articulate this position in which 
they advocate for a patient-centered approach [5]. Research findings suggest 
that a positive association exist between patient-doctor communications in 
diabetes on patient outcomes, for example, good self-management behav-
ior [6–8]. Rubin et al. [8] find that the patient-provider partnership is associ-
ated with more positive ratings on patient-reported outcomes including hy-
perglycemic symptoms, medical regimen adherence, overall wellbeing and 
perceived diabetes control. Other studies also indicate that patient-provider 
communication plays a critical factor in medical adherence [9,10]. Although 
insulin adherence rates among PWDs vary between two-thirds and three-
quarters [11], we argue that the role of physicians may impact the overall 
wellbeing of PWDs based on insulin treatment. Therefore, this research ex-
amines the roles of PWDs and doctors in effectively managing diabetes for 
those on insulin treatment versus who are not on insulin therapy, holding 
all other factors constant. 
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1.1. Treatment guidelines 
Preventing extended high blood sugars is vital to preventing complications 
in PWDs. Additionally, routine physician visits and bloodwork can identify 
the beginnings of complications and prevent their worsening. Given this in-
formation, it is important to consider how treatment standards may vary 
based on not only the type of diabetes, but the form of treatment chosen 
for PWDs [12]. For example, those with type 1 diabetes and those receiving 
intensive insulin therapy must undergo self-monitoring of blood glucose 
levels before and after meals, before and after exercise, at bedtime, when 
low blood sugar is suspected or corrected for, and before activities such as 
driving. In those PWDs with type 2 diabetes and are not on intensive insu-
lin therapy, the recommendations for self-monitoring blood glucose levels 
are not clear [12]. The frequency of home glucose testing is left to the dis-
cretion of the physician, and indirectly, the PWD’s insurance company [12], 
which may not produce an adequate picture of glycemic control. Self-moni-
toring blood glucose levels can help to evaluate treatment efficacy and lower 
average blood sugar levels, leading to better patient outcomes (e.g. lower 
risk of cardiovascular disease). 
1.2. Obstacles to care 
1.2.1. Social construction of diabetes 
The social construction of illness is now a major line of research in the 
medical sociology field. Berger and Luckman [13] defines the phenomenon 
of social constructionism as individuals and groups examining different ideas 
based on their social realities and knowledge. Similarly, Eisenberg [14] pos-
tulated that a social constructionist perspective explores the dissimilarity 
between disease, a biological condition and illness, a social condition. We 
employ this conceptual tool to discuss how the differences in diabetes type 
can be impacted by its social construction. 
The differentiation by type of diabetes (e.g. type 1 vs. type 2) raises con-
cerns about how the disease is socially constructed and how this may af-
fect care outcomes. Because of the associated links of lifestyle (e.g. obe-
sity), those with type 2 diabetes may face higher levels of stigmatization. 
The feelings of stigmatization noted by those with type 2 diabetes is of-
ten due to the widespread belief that type 2 diabetes can be prevented or 
‘cured’ through lifestyle changes [15,16], even though research shows a ge-
netic predisposition [17,18]. The perceived stigma of type 2 diabetes may 
lead to undesirable outcomes, such as attempted concealment of the dis-
ease and suboptimal self-care [15,16]. Moreover, the social construction of 
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type 2 diabetes as a consequence of poor lifestyle can harm relationships 
with care providers. For example, if the PWD is unable to lower blood glu-
cose levels with physician directed lifestyle changes, the perceived non-
compliance of the patient by the medical provider may damage the PWD’s 
trust and ability to communicate with the provider [15,16,19]. There is also 
evidence that those with type 2 diabetes perceive that medical providers 
give more help to, and feel more concern for, those with type 1 diabe-
tes [16]. Additionally, the social construction of diabetes is further rein-
forced by healthcare providers and insurance companies setting different 
standards for the use of medical devices (e.g., glucose monitoring strips, 
pumps, continuous glucose monitors) by type of diabetes, rather than for 
optimal disease management [16]. 
1.2.2. Social determinants of diabetes care outcomes 
Diabetes places a good deal of financial pressure on PWDs and their fam-
ilies. Studies have shown that PWDs who come from lower socioeconomic 
conditions struggle more with food insecurity [20] and lower compliance 
rates [21]. Even with the Affordable Care Act in place, diabetes care and sup-
plies are expensive and insurance companies do not always provide ade-
quate coverage, even when the technology improves outcomes for PWDs 
(e.g. continuous glucose monitors) [22–25]. PWDs have reported reducing 
insulin and medication dosing, as well as reducing the number of physician 
visits to cut costs [21]. Many physicians and insurance companies believe 
that insulin therapy requires much more intensive self-management than 
for those not on insulin therapy, which may reduce referrals to specialists, 
lead to prescriptions for fewer blood glucose test strips, and a lower num-
ber of preventative tests [22–25]. 
The purpose of the current study is to better understand the impact of 
insulin therapy on diabetes care outcomes, while controlling for socioeco-
nomic factors, healthcare access, and self-reported physical and mental 
health. We propose the following hypothesis that PWDs on insulin ther-
apy will have greater access to self-monitoring blood glucose testing (H1), 
perform more self-checks of their feet (H2), be more likely to attend dia-
betes education classes (H3), more likely to see their physician (H4), have 
their A1C tested (H5), have diabetic foot checks in the physician’s office 
(H6) and be more aware of their complications of diabetes, including di-
abetic retinopathy and kidney disease (H7) than those who were not on 
insulin therapy. 
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2. Methods 
2.1. Data and participants 
This study utilizes the Behavioral Risk Factor Surveillance System Survey 
(BRFSS) data collected in 2015. The BRFSS collects behavioral risk factors 
from survey participants throughout the United States, and is one of the 
most powerful tools in targeting and building health promotions activities 
[26]. The telephone based BRFSS coordinated by the Centers for Disease 
Control (CDC) is completed by health departments in all fifty states, and in-
cludes Puerto Rico, D.C., and Guam. The BRFSS collects information from 
adults 18 years of age and older utilizing both core and optional supple-
mental survey modules to fit a specific state’s needs. The supplemental sur-
vey module for Diabetes was collected by 32 states in 2015. 
2.2. Measures 
2.2.1. Insulin therapy 
The primary predictor variable, self-reported use of insulin, was measured 
with the question ‘Are you now taking insulin?’ Those considered to be on 
insulin therapy responded yes to this question. The BRFSS does not distin-
guish between the types of diabetes diagnosed. 
2.2.2. Outcomes 
Three outcomes were assessed for this paper; selfmanagement of diabe-
tes, diabetes care quality, and complications related to diabetes. Compliance 
to treatment standards, and therefore the cutoff points for the variables, are 
done in accordance to the American Diabetes Association’s guidelines for 
treatment standards [12]. 
2.2.3. Self-management of diabetes 
Three questions measured the quality of self-management of a respon-
dent: self-monitoring of blood glucose level and self-administered foot ex-
aminations (daily vs. weekly or more) and if the respondent had ever at-
tended a diabetes education course (yes vs. no). 
2.2.4. Diabetes care quality 
Four questions were used in assessing quality of diabetes care provided 
to the respondent in the past twelve months: number of primary care vis-
its related to diabetes (2–5 vs. other), foot exams administered by provider 
(more than 2 vs. 0–1), number of times an HbA1c was drawn (1–4 vs. other), 
and time since last dilated eye exam (less than a year vs. more than a year). 
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2.2.5. Diabetes complications 
Two questions were used to assess the presence of diabetic complica-
tions. The first asked the respondent if they had been told they had kidney 
disease, and the second asked if the respondent had been told that they 
had diabetic retinopathy. 
2.2.6. Covariates 
Diabetes outcomes are influenced by sociodemographic factors, as well 
as the ability to access healthcare services and not only the physical, but 
mental health of the PWDs. Because of this, these factors were included and 
controlled for in the models. 
2.2.7. Sociodemographic factors 
Race was measured as a dichotomous variable of white versus non-white 
due to the small sample sizes of other racial and ethnic groups. Education, 
used as a proxy for social class, was measured as a dichotomous variable of 
high school or less versus some college or more. Age was measured as a di-
chotomous variable of either under 65 or over 65. 
2.2.8. Self-reported health 
Self-reported health status was measured as a dichotomous variable of 
either good or better health versus fair or worse health. Mental health was 
measured as the count of the number of days a PWDs reported poor men-
tal health. Comorbidities including hypertension, hyperlipidemia, previous 
myocardial infarction, coronary heart disease, and previous stroke were each 
measured by answering in the affirmative to the diagnosis of the condition. 
Body Mass Index (BMI) was measured as a dichotomous variable of either 
under 25 (under or normal weight) or over 25 (overweight or obese). 
2.2.9. Access to care 
Access to care was measured in two ways; a dichotomous variable of 
having insurance coverage or not, and a separate dichotomous variable re-
flecting whether the respondent had faced medical hardship in the past 12 
months. 
2.3. Data analysis 
First, descriptive statistics were run to determine the composition of the 
sample after the listwise deletion of any participant missing data. Then, lo-
gistic regression analysis was completed describing associations with insu-
lin therapy and self-management of diabetes (i.e. self-checks of blood glu-
cose), diabetes care quality (i.e. number of HbA1c tests performed every 12 
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months), and diabetes-related complications (i.e. kidney disease and dia-
betic retinopathy). Each hypothesis was tested with each of the nine vari-
ables under the larger headings, rather than as an aggregate variable. The 
models were adjusted for the following variables: 1) sociodemographic fac-
tors (age, sex, race and education), 2) access to healthcare (insurance cover-
age and medical hardship), and 3) self-reported physical and mental health. 
Each set of variables were modeled independently and the overall model 
was built in steps (i.e., Model 1 including only sociodemographic factors 
and Model 2 including sociodemographic factors and access to healthcare 
and Model 3 including sociodemographic factors, access to healthcare and 
self-reported physical health). The aim of the models is to understand if the 
method of treatment (insulin therapy vs. non-insulin therapy) has an effect 
on outcomes when controlling for the typical contributors to poor diabe-
tes outcomes. Statistical significance was determined at the p ≤ 0.05 level. 
3. Results 
3.1. Sample characteristics 
Of those respondents in the BRFSS who answered yes to having been diag-
nosed with diabetes, more than one-third (38.6%) are insulin users. Almost 
three-quarter of the sample is white (72.2%) and females comprise more 
than half (53.9%) of the respondents. Respondents over 65 years of age ac-
counted for 51.7% of the sample and almost 60% of respondents obtained 
a college education or higher. Slightly more than three-quarters (76.8%) of 
the respondents reported having hypertension, and two-thirds (66.7%) re-
ported having hyperlipidemia. The respondents who reported having had 
a myocardial infraction and coronary heart disease were in the minority 
with 14.9% and 15.9% respectively. Almost one in ten (9.5%) respondents 
reported having experienced a stroke and nearly nine in ten respondents 
have a Body Mass Index (BMI) of over 25. A little more than two-fifth (41%) 
respondents selfreported that their health status was good or better and 
most respondents (96%) have health insurance and only 10% report having 
any medical hardship (Table 1). 
3.2. Insulin therapy and self-management of diabetes 
As shown in Table 2, approximately three-fourths of the respondents re-
ported checking their blood glucose and their feet on a daily basis, and two-
thirds of respondents reported having attended a diabetes education pro-
gram (Table 2). Respondents’ who report using insulin to treat their diabetes 
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Table 1. Sample demographics of respondents with diabetes.
  Total (n = 15,409)  Proportion
Insulin use
 Yes  5,957  38.66
 No  9,452  61.34
Race
 White  11,130  72.23
 Non-white  4,279  27.77
Sex
 Male  7,092  46.03
 Female  8,317  53.97
Age
 Under 65  7,441  48.29
 Over 65  7,968  51.71
Education
 High school or less  6,311  40.96
 College or more  9,098  59.04
Hypertension
 Yes  10,703  76.82
 No  3,229  23.18
Hyperlipidemia
 Yes  9,292  66.70
 No  4,640  33.30
Myocardial infarction
 Yes  2,076  14.90
 No  11,856  85.10
Coronary heart disease
 Yes  2,223  15.96
 No  11,709  84.04
Stroke
 Yes  1,327  9.52
 No  12,605  90.48
Body mass index (BMI)
 Under 25 1,830  13.14
 Over 25  12,102  86.86
Health status
 Good or better  9,087  41.03
 Fair or worse  6,322  58.97
Health insurance status
 Insured  14,844  96.33
 No insurance  565  3.67
Medical hardship
 Yes  1,596  10.36
 No  13,813  89.64
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were more likely to check blood glucose levels daily at home (OR 7.57, p < 
.001), check their feet on a daily basis (OR 1.27, p < .001), and attend a dia-
betes education class (OR 1.96, p < .001), when controlled for sociodemo-
graphic information, self-reported health, and access to care (Table 3). 
3.3. Insulin therapy and diabetes care quality 
In Table 2, approximately two-thirds of respondents reported seeing their 
primary care provider two to five times a year in regards to diabetes as well 
as report having provider administered foot checks within the recommended 
compliance standards. A majority of respondents (89.7%) reported having 
their HbA1c drawn at the recommended care guidelines. Three-fourths of 
the respondents reported having a dilated eye exam within the past twelve 
months (Table 2). Respondents who reported insulin use were more likely 
to meet care guidelines for doctor visits (OR 1.24, p < .001), provider admin-
istered foot examinations (OR 1.80, p < .001), and dilated eye examinations 
Table 2. Bivariate associations between insulin therapy and diabetes health outcomes.
	 Compliance	 Proportion	meeting	 Unadjusted	 P-value		 95%	confidence
 level compliance levels odds ratio  interval
Self-management of diabetes
Self-monitoring of (Daily vs. weekly .725  7.74  ***  (6.99, 8.59) 
   blood glucose    or more)
Self-administered (Daily vs. weekly
   foot examinations    or more) .710  1.23  ***  (1.15, 1.33)
Attended diabetes (Yes vs. no) .639  1.91  ***  (1.78, 2.05)
   class
Diabetes care quality (previous 12 months)
Number of primary (2–5 times per .677  1.13  ***  (1.05, 1.21)
   care visits    year vs. other)
Provider-administered (More than 2 .610  1.84  ***  (1.72, 1.97)
   foot examinations    vs. 0–1)
Number of times (1–4 vs other)  .897  0.88  **  (0.79, 0.97)
   HbA1c drawn
Dilated eye exam  (Less than vs .746  1.22  ***  (1.13, 1.31)
    more than 1 year)
Proportion reporting condition
Diabetes complications
Kidney disease  (Yes vs. no)  .111  2.53  ***  (2.28, 2.80)
Diabetic retinopathy  (Yes vs. no)  .200  3.04  ***  (2.80, 3.29)
+ p < .10 ; * p < .05 ; ** p < .01 ; *** p < .001
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(OR 1.34, p < .001). In regards to the HbA1c tests, however, there were no 
significant differences found between the two groups (OR 1.02, p = .49) 
when controlled for sociodemographic information, self-reported health, 
and access to care (Table 3). 
3.4. Insulin therapy and complications 
Approximately 11% of respondents reported having kidney disease and 20% 
reported having been diagnosed with diabetic retinopathy (Table 2). It is 
more likely for a respondent using insulin to report kidney disease (OR 2.14, 
p < .001) and/or diabetic retinopathy (OR 2.77, p < .001) when controlled for 
sociodemographic information, health status, and access to care (Table 3). 
Table 3. Multivariate associations between insulin therapy and diabetes health outcomes.
 Model 1: 95% Model 2: 95% Model 3: 95%
	 socio-	 confidence	 socio-	 confidence	 sociodemo-	 confidence 
 demographic interval demographic interval graphic  interval
 factors  factors   factors, health
   and health  status, and
   status  healthcare access
Diabetes self-management
Self-monitoring 7.87***  (7.05, 8.78)  7.57***  (6.78, 8.45)  7.57***  (6.78, 8.45)
   of blood glucose
Self-administered 1.27***  (1.18, 1.37)  1.27***  (1.17, 1.37)  1.27***  (1.17, 1.37)
   foot examinations
Attended 1.90***  (1.77, 2.06)  1.96***  (1.82, 2.12)  1.96***  (1.81, 2.18)
   diabetes class
Diabetes care quality (previous 12 months)
Number of 1.14***  (1.06, 1.23)  1.24***  (1.15, 1.34)  1.24***  (1.15, 1.34)
   primary care visits
Provider-administered 1.83***  (1.70, 1.97)  1.80***  (1.67, 1.94)  1.80***  (1.67, 1.94)
   foot examinations 
Number of times .91  (.81, 1.02)  1.02  (.91, 1.15)  1.02  (.90, 1.15)
   HbA1c drawn
Dilated eye exam  1.27***  (1.17, 1.38)  1.35***  (1.24, 1.46)  1.34***  (1.24, 1.46)
Diabetes complications
Kidney disease  2.56***  (2.30, 2.86)  2.15 ***  (1.92, 2.40)  2.14***  (1.91, 2.40)
Diabetic retinopathy 3.07***  (2.81, 3.35)  2.77***  (2.53, 3.02)  2.77***  (2.53, 3.02)
* p < .05 ; ** p < .01 ; *** p < .001
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4. Discussion 
This study shows that even with the small reductions in the statistical asso-
ciations when accounting for sociodemographic factors and health status, 
the use of insulin was associated with better care outcomes for those with 
diabetes. The findings of this study support the majority of the hypothesized 
results. Those who are on insulin therapy are more likely to do self-checks 
of their blood glucose levels and feet on a daily basis, and are more likely 
to have taken a recommended diabetes education class. Furthermore, those 
on insulin therapy are more likely to meet recommended numbers of physi-
cian visits and provider-administered foot checks, however, little difference 
was seen for HbA1c tests. Finally, there is a higher likelihood of self-report-
ing complications of diabetes, such as kidney disease and diabetic retinop-
athy, among respondents using insulin to treat their diabetes. 
One theory of preventing poor outcomes in PWDS is the adequate co-
involvement of the PWDs, their support system, and the healthcare team 
[27]. These results show that there is a higher likelihood of PWDs on insulin 
to be more invested in their self-care and to have more involvement with 
their providers. The reason behind this may be two-fold; PWDs who are on 
insulin therapy may have had higher HbA1c levels, requiring more intensive 
care [27], and those on insulin therapy may have more access to and better 
coverage for diabetes supplies and associated care. In addition, PWDs who 
are type 1, or on intensive insulin therapy, may have better overall relation-
ships with their providers due to a reduction in stigmatization. The reduc-
tion in stigmatization felt by the PWDs may lead to more trust in and bet-
ter communication with their provider as well as less reluctance to engage 
in self-care. Overall, a benefit to having this access is PWDs on insulin are 
more likely to be aware of and self-report their complications. 
There are a few limitations to this study. First, the type of diabetes that 
has been diagnosed is unclear. PWDs treated with insulin may be either 
type 1, or type 2 who have not had a good response to oral medications, 
changes in diet, or developed a reduction in insulin production as a conse-
quence of time and higher glucose levels. Previous studies have shown that 
people with type 2 diabetes may have different beliefs about their health 
risks from diabetes and resulting complications, which may adversely affect 
their health (i.e. diabetic foot ulcers) [28]. Additionally, there is no informa-
tion on one of the more common complications of diabetes, neuropathy, 
and its associated risk of amputation of the lower limbs. This, in combina-
tion with the type of diabetes, may give a broader picture of the importance 
of having care guidelines that are the same across all PWDs, regardless of 
type and treatment choice. 
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